The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo

C. Joyce, M. Boyd, A. Sorensen, M. Tesson, J. W. Babich, R. J. Mairs

Research output: Contribution to journalConference Contribution

Abstract

This study investigates the potential of the noradrenaline analogue [131I]MIBG (metaiodobenzylguanidine) and the novel melanin binding benzamide [131I]
Solazed for melanoma therapy in vivo and in vitro.
Original languageEnglish
Pages (from-to)110-110
Number of pages1
JournalMutagenesis
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2012
Event34th Annual Meeting of the United Kingdom Environmental Mutagen Society - Nottingham, United Kingdom
Duration: 29 Jun 20111 Jul 2011

Keywords

  • targeted radionuclide therapy
  • treatment
  • malignant melanoma
  • in vivo
  • in vitro
  • noradrenaline analogue
  • metaiodobenzylguanidine

Fingerprint Dive into the research topics of 'The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo'. Together they form a unique fingerprint.

Cite this